Deciphera Pharmaceuticals, a biopharmaceutical company dedicated to discovering and developing innovative medicines to improve the lives of cancer patients, has announced the pricing of a public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share. The offering is expected to generate approximately $125 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1,041,666 shares of common stock. The offering is anticipated to close on January 24, 2023, subject to the completion of customary closing conditions.
With the proceeds from the offering, Deciphera intends to embark on a series of ambitious initiatives to advance its research and development. These initiatives include the Phase 3 INSIGHT study of QINLOCK® versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18; the development of vimseltinib, including the Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients; and the development of DCC-3116, with multiple expansion cohorts in the ongoing Phase 1b combination dose escalation studies and potential Phase 2 expansion combination cohorts in multiple tumor types. In addition, Deciphera intends to fund its pan-RAF program, and may explore the development of a new candidate and other new research activities from its proprietary discovery engine of novel switch control inhibitors. Finally, the remaining proceeds will be used for working capital purposes, such as general operating expenses.
J.P. Morgan, Jefferies, Cowen, and Guggenheim Securities are joining forces to launch a new offering, acting as joint book-running managers. This exciting collaboration is sure to bring about great success for the venture.
Deciphera is offering securities pursuant to an effective shelf registration statement approved by the Securities and Exchange Commission (SEC) on August 10, 2022. A preliminary prospectus supplement and accompanying prospectus outlining the terms of the offering has already been filed with the SEC. To obtain a copy of the final prospectus supplement and accompanying prospectus, contact J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC or Guggenheim Securities, LLC.
We are pleased to announce the offering of new securities but these securities are not available for sale until they have been registered or qualified under the applicable securities laws of the relevant state or jurisdiction. Don’t miss out on this unique opportunity to invest!
About Deciphera Pharmaceuticals
At Deciphera, we are dedicated to revolutionizing cancer treatment and improving the lives of people in need. Our state-of-the-art switch-control kinase inhibitor platform and extensive knowledge in kinase biology have enabled us to develop a broad range of groundbreaking medicines. We have several product candidates in clinical studies and have already seen success with the approval of our switch control inhibitor, QINLOCK®, for the treatment of fourth-line GIST in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.